Aggregation-induced emission (AIE) dye loaded polymer nanoparticles for gene silencing in pancreatic cancer and their in vitro and in vivo biocompatibility evaluation
),
Ben Zhong Tang3(
)
Download citation
506
Views
10
Downloads
36
Crossref
N/A
WoS
38
Scopus
6
CSCD
We have developed aggregation-induced emission (AIE) dye loaded polymer nanoparticles with deep-red emission for siRNA delivery to pancreatic cancer cells. Two US Food and Drug Administration (FDA) approved surfactant polymers, Pluronics F127 and PEGylated phospholipid, were used to prepare the dye-loaded nanoparticle formulations and they can be used as nanovectors for gene silencing of mutant K-ras in pancreatic cancer cells. The successful transfection of siRNA by the developed nanovectors was confirmed by the fluorescent imaging and quantified through flow cytometry. Quantitative real time polymerase chain reaction (PCR) indicates that the expression of the mutant K-ras oncogene from the MiaPaCa-2 pancreatic cancer cells has been successfully suppressed. More importantly, our in vivo toxicity study has revealed that both the nanoparticle formulations are highly biocompatible in BALC/c mice. Overall, our results suggest that the AIE dye-loaded polymer nanoparticle formulations developed here are suitable for gene delivery and have high potential applications in translational medicine research.
menu
Aggregation-induced emission (AIE) dye loaded polymer nanoparticles for gene silencing in pancreatic cancer and their in vitro and in vivo biocompatibility evaluation
), Ben Zhong Tang3(
)
Abstract
We have developed aggregation-induced emission (AIE) dye loaded polymer nanoparticles with deep-red emission for siRNA delivery to pancreatic cancer cells. Two US Food and Drug Administration (FDA) approved surfactant polymers, Pluronics F127 and PEGylated phospholipid, were used to prepare the dye-loaded nanoparticle formulations and they can be used as nanovectors for gene silencing of mutant K-ras in pancreatic cancer cells. The successful transfection of siRNA by the developed nanovectors was confirmed by the fluorescent imaging and quantified through flow cytometry. Quantitative real time polymerase chain reaction (PCR) indicates that the expression of the mutant K-ras oncogene from the MiaPaCa-2 pancreatic cancer cells has been successfully suppressed. More importantly, our in vivo toxicity study has revealed that both the nanoparticle formulations are highly biocompatible in BALC/c mice. Overall, our results suggest that the AIE dye-loaded polymer nanoparticle formulations developed here are suitable for gene delivery and have high potential applications in translational medicine research.
References(76)
Ginn S. L.; Alexander, I. E.; Edelstein, M. L.; Abedi, M. R.; Wixon, J. Gene therapy clinical trials worldwide to 2012— an update. J. Gene Med. 2013, 15, 65-77.
Peer D.; Lieberman J. Special delivery: targeted therapy with small RNAs. Gene Ther. 2011, 18, 1127-1133.
Agrawal N.; Dasaradhi P. V. N.; Mohmmed A.; Malhotra P.; Bhatnagar R. K.; Mukherjee S. K. RNA Interference: Biology, Mechanism, and Applications. Microbiol. Mol. Biol. R. 2003, 67, 657-685.
Nykänen A.; Haley B.; Zamore P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001, 107, 309-321.
Wang J.; Lu Z.; Wientjes M. G.; Au J. L. -S. Delivery of siRNA therapeutics: Barriers and carriers. AAPS J. 2010, 12, 492-503.
Yin H.; Kanasty R. L.; Eltoukhy A. A.; Vegas A. J.; Dorkin J. R.; Anderson D. G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15, 541-555.
Medarova Z.; Pham W.; Farrar C.; Petkova V.; Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 2007, 13, 372-377.
Lee J. H.; Lee K.; Moon S. H.; Lee Y.; Park T. G.; Cheon J. All-in-One Target-Cell-Specific Magnetic Nanoparticles for Simultaneous Molecular Imaging and siRNA Delivery. Angew. Chem. Int. Ed. 2009, 121, 4238-4243.
Meng H.; Liong M.; Xia T.; Li Z.; Ji Z.; Zink J. I.; Nel A. E. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4, 4539-4550.
Everts M.; Saini V.; Leddon J. L.; Kok R. J.; Stoff-Khalili M.; Preuss M. A.; Millican C. L.; Perkins G.; Brown J. M.; Bagaria H. Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett. 2006, 6, 587-591.
Nasongkla N.; Bey E.; Ren J.; Ai H.; Khemtong C.; Guthi J. S.; Chin S. -F.; Sherry A. D.; Boothman D. A.; Gao J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006, 6, 2427-2430.
Farokhzad O. C.; Langer R. Impact of Nanotechnology on Drug Delivery. ACS Nano 2009, 3, 16-20.
Chen R. F.; Knutson J. R. Mechanism of fluorescence concentration quenching of carboxyfluorescein in liposomes: Energy transfer to nonfluorescent dimers. Anal. Biochem. 1988, 172, 61-77.
Shirai K.; Matsuoka M.; Fukunishi K. Fluorescence quenching by intermolecular π-π interactions of 2, 5-bis(N, N-dialkylamino)-3, 6-dicyanopyrazines. Dyes Pigm. 1999, 42, 95-101.
Hong Y.; Lam J. W.; Tang B. Z. Aggregation-induced emission: phenomenon, mechanism and applications. Chem. Commun. 2009, 4332-4353.
Hong Y.; Lam J. W. Y.; Tang B. Z. Aggregation-induced emission. Chem. Soc. Rev. 2011, 40, 5361-5388.
Luo J.; Xie Z.; Lam J. W. Y.; Cheng L.; Chen H.; Qiu C.; Kwok H. S.; Zhan X.; Liu Y.; Zhu D.; Tang B. Z. Aggregation-induced emission of 1-methyl-1, 2, 3, 4, 5-pentaphenylsilole. Chem. Commun. 2001, 1740-1741.
Wang Z.; Chen S.; Lam J. W. Y.; Qin W.; Kwok R. T. K.; Xie N.; Hu Q.; Tang B. Z. Long-Term Fluorescent Cellular Tracing by the Aggregates of AIE Bioconjugates. J. Am. Chem. Soc. 2013, 135, 8238-8245.
Tseng N. -W.; Liu J.; Ng J. C. Y.; Lam J. W. Y.; Sung H. H. Y.; Williams I. D.; Tang B. Z. Deciphering mechanism of aggregation-induced emission (AIE): Is E-Z isomerisation involved in an AIE process Chem. Sci. 2012, 3, 493-497.
Wang P.; Yan X.; Huang F. Host-guest complexation induced emission: a pillar[6]arene-based complex with intense fluorescence in dilute solution. Chem. Commun. 2014, 50, 5017-5019.
Ding D.; Li K.; Liu B.; Tang B. Z. Bioprobes Based on AIE Fluorogens. Acc. Chem. Res. 2013, 46, 2441-2453.
Qin W.; Ding D.; Liu J.; Yuan W. Z.; Hu Y.; Liu B.; Tang B. Z. Biocompatible Nanoparticles with Aggregation-Induced Emission Characteristics as Far-Red/Near-Infrared Fluorescent Bioprobes for In Vitro and In Vivo Imaging Applications. Adv. Funct. Mater. 2012, 22, 771-779.
Pai A. S.; Rubinstein I.; Önyüksel H. PEGylated phospholipid nanomicelles interact with β-amyloid(1-42) and mitigate its β-sheet formation, aggregation and neurotoxicity in vitro. Peptides 2006, 27, 2858-2866.
Jokerst J. V.; Lobovkina T.; Zare R. N.; Gambhir S. S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine—UK 2011, 6, 715-728.
Shishido S. l. M.; Seabra A. B.; Loh W.; Ganzarolli de Oliveira M. Thermal and photochemical nitric oxide release from S-nitrosothiols incorporated in Pluronic F127 gel: potential uses for local and controlled nitric oxide release. Biomaterials 2003, 24, 3543-3553.
Liaw J.; Lin Y. -C. Evaluation of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl. J. Control. Release 2000, 68, 273-282.
Smit V. T.; Boot A. J.; Smits A. M.; Fleuren G. J.; Cornelisse C. J.; Bos J. L. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988, 16, 7773-7782.
Haigis K. M.; Kendall K. R.; Wang Y.; Cheung A.; Haigis M. C.; Glickman J. N.; Niwa-Kawakita M.; Sweet-Cordero A.; Sebolt-Leopold J.; Shannon K. M. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 2008, 40, 600-608.
Campbell P. M.; Groehler A. L.; Lee K. M.; Ouellette M. M.; Khazak V.; Der C. J. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 2007, 67, 2098-2106.
Dreissigacker U.; Mueller M. S.; Unger M.; Siegert P.; Genze F.; Gierschik P.; Giehl K. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell. Signal. 2006, 18, 1156-1168.
Lin G.; Yang C.; Hu R.; Chen C. -K.; Law W. -C.; Anderson T.; Zhang B.; Nguyen Q. T.; Toh H. T.; Yoon H. S.; Cheng C.; Yong K. -T. Interleukin-8 gene silencing on pancreatic cancer cells using biodegradable polymer nanoplexes. Biomater. Sci. 2014, 2, 1007-1015.
Yang C.; Mo X.; Lv J.; Liu X.; Yuan M.; Dong M.; Li L.; Luo X.; Fan X.; Jin Z. Lipopolysaccharide enhances FcεRI-mediated mast cell degranulation by increasing Ca2+ entry through store-operated Ca2+ channels: implications for lipopolysaccharide exacerbating allergic asthma. Exp. Physiol. 2012, 97, 1315-1327.
Thellin O.; Zorzi W.; Lakaye B.; De Borman B.; Coumans B.; Hennen G.; Grisar T.; Igout A.; Heinen E. Housekeeping genes as internal standards: use and limits. J. Biotechnol. 1999, 75, 291-295.
Lin G.; Hu R.; Law W. -C.; Chen C. -K.; Wang Y.; Li Chin H.; Nguyen Q. T.; Lai C. K.; Yoon H. S.; Wang X.; Xu G.; Ye L.; Cheng C.; Yong K. -T. Biodegradable Nanocapsules as siRNA Carriers for Mutant K-Ras Gene Silencing of Human Pancreatic Carcinoma Cells. Small 2013, 9, 2757-2763.
Benrraou M.; Bales B. L.; Zana R. Effect of the nature of the counterion on the properties of anionic surfactants. 1. Cmc, ionization degree at the cmc and aggregation number of micelles of sodium, cesium, tetramethylammonium, tetraethylammonium, tetrapropylammonium, and tetrabutylammonium dodecyl sulfates. J Phys. Chem. B 2003, 107, 13432-13440.
Balsara N. P.; Tirrell M.; Lodge T. P. Micelle formation of BAB triblock copolymers in solvents that preferentially dissolve the A block. Macromolecules 1991, 24, 1975-1986.
Chu B. Structure and dynamics of block copolymer colloids. Langmuir 1995, 11, 414-421.
Smart T.; Lomas H.; Massignani M.; Flores-Merino M. V.; Perez L. R.; Battaglia G. Block copolymer nanostructures. Nano Today 2008, 3, 38-46.
Wendoloski J.; Kimatian S.; Schutt C.; Salemme F. Molecular dynamics simulation of a phospholipid micelle. Science 1989, 243, 636-638.
Wang D.; Qian J.; Qin W.; Qin A.; Tang B. Z.; He S. Biocompatible and Photostable AIE Dots with Red Emission for In vivo Two-Photon Bioimaging. Sci. Rep. 2014, 4.
Wang J.; Fang X.; Liang W. Pegylated Phospholipid Micelles Induce Endoplasmic Reticulum-Dependent Apoptosis of Cancer Cells but not Normal Cells. ACS nano 2012, 6, 5018-5030.
IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man; World Health Organization: Lyon1999.
Beddowes E. J.; Faux S. P.; Chipman J. K. Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress. Toxicology 2003, 187, 101-115.
Varkouhi A. K.; Scholte M.; Storm G.; Haisma H. J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151, 220-228.
El-Sayed A.; Futaki S.; Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 2009, 11, 13-22.
Horth M.; Lambrecht B.; Khim M. C. L.; Bex F.; Thiriart C.; Ruysschaert J. -M.; Burny A.; Brasseur R. Theoretical and functional analysis of the SIV fusion peptide. EMBO J. 1991, 10, 2747-2755.
Marsh M.; Helenius A. Virus Entry into Animal Cells. In Advances in Virus Research Maramorosch K, Murphy FA, Shatkin AJ, Eds.; Elsevier. 1989; pp. 107-151.
Felgner P. L.; Gadek T. R.; Holm M.; Roman R.; Chan H. W.; Wenz M.; Northrop J. P.; Ringold G. M.; Danielsen M. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Nat. Acad. Sci. U.S.A. 1987, 84, 7413-7417.
Farhood H.; Serbina N.; Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta, Biomembr. 1995, 1235, 289-295.
Zhou X.; Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim. Biophys. Acta, Biomembr. 1994, 1189, 195-203.
Nel A. E.; Madler L.; Velegol D.; Xia T.; Hoek E. M. V.; Somasundaran P.; Klaessig F.; Castranova V.; Thompson M. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009, 8, 543-557.
Boussif O.; LezoualC'H F.; Zanta M. A.; Mergny M. D.; Scherman D.; Demeneix B.; Behr J. P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Nat. Acad. Sci. U.S.A. 1995, 92, 7297-7301.
Pattrick N. G.; Richardson S. C. W.; Casolaro M.; Ferruti P.; Duncan R. Poly(amidoamine)-mediated intracytoplasmic delivery of ricin A-chain and gelonin. J. Control. Release 2001, 77, 225-232.
Mellman I.; Fuchs R.; Helenius A. Acidification of the Endocytic and Exocytic Pathways. Annu. Rev. Biochem. 1986, 55, 663-700.
Patil Y.; Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int. J. Pharm. 2009, 367, 195-203.
Thomas J. L.; Tirrell D. A. Polyelectrolyte-sensitized phospholipid vesicles. Acc. Chem. Res. 1992, 25, 336-342.
Wickner W.; Schekman R. Membrane fusion. Nat. Struct. Mol. Biol. 2008, 15, 658-664.
Hruban R. H.; Petersen G. M.; Ha P. K.; Kern S. E. Genetics of pancreatic cancer. From genes to families. Surg. Oncol. Clin. N. Am. 1998, 7, 1-23.
Yamanaka Y.; Friess H.; Kobrin M. S.; Büchler M.; Kunz J.; Beger H. G.; Korc M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. 1993, 24, 1127-1134.
Goldstein A. M.; Fraser M. C.; Struewing J. P.; Hussussian C. J.; Ranade K.; Zametkin D. P.; Fontaine L. S.; Organic S. M.; Dracopoli N. C.; Clark Jr W. H. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16 INK4 mutations. New Engl. J. Med. 1995, 333, 970-975.
Pellegata N. S.; Sessa F.; Renault B.; Bonato M.; Leone B. E.; Solcia E.; Ranzani G. N. K-ras and p53 Gene Mutations in Pancreatic Cancer: Ductal and Nonductal Tumors Progress through Different Genetic Lesions. Cancer Res. 1994, 54, 1556-1560.
Murphy K. M.; Brune K. A.; Griffin C.; Sollenberger J. E.; Petersen G. M.; Bansal R.; Hruban R. H.; Kern S. E. Evaluation of Candidate Genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 Mutations in 17%. Cancer Res. 2002, 62, 3789-3793.
Li D.; Xie K.; Wolff R.; Abbruzzese J. L. Pancreatic cancer. Lancet 2004, 363, 1049-1057.
Almoguera C.; Shibata D.; Forrester K.; Martin J.; Arnheim N.; Perucho M. Most human carcinomas of the exocrine pancreas contain mutant cK-ras genes. Cell 1988, 53, 549-554.
Lowy D.; Willumsen B. Function and regulation of ras. Annu. Rev. Biochem. 1993, 62, 851-891.
Trahey M.; McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987, 238, 542-545.
Arlt A.; Muerkoster S. S.; Schafer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2013, 332, 346-358.
Takashima A.; Faller D. V. Targeting the RAS oncogene. Expert Opin. Ther. Tar. 2013, 17, 507-531.
Tsuchida T.; Kijima H.; Hori S.; Oshika Y.; Tokunaga T.; Kawai K.; Yamazaki H.; Ueyama Y.; Scanlon K. J.; Tamaoki N.; Nakamura M. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther. 2000, 7, 373-383.
Jasinski P.; Zwolak P.; Terai K.; Dudek A. Z. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. Transl. Res. 2008, 152, 203-212.
Miura Y.; Ohnami S.; Yoshida K.; Ohashi M.; Nakano M.; Ohnami S.; Fukuhara M.; Yanagi K.; Matsushita A.; Uchida E.; Asaka M.; Yoshida T.; Aoki K. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett. 2005, 218, 53-62.
Brummelkamp T. R.; Bernards R.; Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2, 243-247.
Yoshikawa K.; Tanabe E.; Shibata A.; Inoue S.; Kitayoshi M.; Okimoto S.; Fukushima N.; Tsujiuchi T. Involvement of oncogenic K-ras on cell migration stimulated by lysophosphatidic acid receptor-2 in pancreatic cancer cells. Exp. Cell. Res. 2013, 319, 105-112.
Fleming J. B.; Shen G. L.; Holloway S. E.; Davis M.; Brekken R. A. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy. Mol. Cancer Res. 2005, 3, 413-423.
Publication history
Copyright
Acknowledgements
This work was supported by the National Natural Science Foundation of China (NSFC) (61107017, 81301318), the Start-up grant (M4080141.040) from Nanyang Technological University, Tier 1 Academic Research Funds (M4010360.040 RG29/10) from Singapore Ministry of Education and partially from the Singapore Ministry of Education under a Tier 2 Research Grant MOE2010-T2-2-010 (4020020.040 ARC2/11) and the grant from the Shenzhen Basic Research Project (JC201005280391A)
FEEDBACK 
TOP